T2 Biosystems, Inc. (NASDAQ:TTOO) CEO Q2 2022 Results Earnings Conference Call August 15, 2022 4:30 PM ET
Company Participants
Emma Poalillo – Investor Relations, Gilmartin Group
John Sperzel – Chairman and Chief Executive Officer
John Sprague – Chief Financial Officer
Conference Call Participants
Stephen Brozak – WBB Securities
Operator
Good day and welcome to T2 Biosystems Second Quarter 2022 Earnings Conference Call. All participants are in listen-only mode. [Operator Instructions]. Please note this event is being recorded.
I would now like to turn the conference over to Emma Poalillo.
Emma Poalillo
Thank you, operator. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Those include statements related to T2 Biosystems’ future financial and operating results and plans for developing and marketing new products.
Forward-looking statements are based on estimates and assumptions as of today and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by these statements, including the risks and uncertainties described in T2 Biosystems’ annual report on Form 10-K filed with the SEC on March 23, 2022, and other filings the company makes with the SEC from time-to-time. The company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.
With that, I would like to turn the call over to Chairman and CEO, John Sperzel. John?
John Sperzel
Thank you all for joining our second quarter 2022 earnings call. I’ll start with an overview of our performance during the second quarter, and provide an update on our commercial, operational and new product pipeline progress. I will then turn the call over to our Chief Financial Officer, John Sprague, to review our second quarter financial results before I provide closing remarks and we open the call for questions and answers.
First, I’d like to comment briefly on today’s filings, including our press release and Form 10-Q to disclose the results our business operations during the second quarter of 2022 and our preliminary proxy to disclose the proposals to be voted on at the annual stockholder meeting to be held on October 11, 2022. We planned the filing of these documents to coincide with today’s call to facilitate open and transparent communication with our stockholders. We will address each of these during our prepared remarks.
During the second quarter, we took actions to improve our cost structure and our balance sheet. On June 1, we implemented workforce and expense reductions that we expect to yield operating expense reductions of approximately 20% and should favorably impact the second half of 2022. It’s important to note that we did not reduce positions in sales or in manufacturing.
We have also recently strengthened our balance sheet by utilizing the ATM facility to raise $27.4 million of net proceeds, including $4.5 million during the second quarter and $22.9 million after the end of the second quarter. Together these actions are intended to reduce our cash burn, increase our cash runway and shorten our path to profitability.
We continue to focus on three corporate priorities, accelerating our sales, enhancing our operations and advancing our pipeline. During the second quarter, our commercial team continued to expand the installed base of T2Dx instruments to increase sepsis test sales, our operations team implemented changes to increase product gross margins, and our R&D team met key development milestones to advance our new product pipeline.
Before I provide an update on our corporate priorities, I’d like to remind you of the importance behind our mission to fundamentally change the way medicine is practiced through transformative culture-independent diagnostics to improve the lives of patients around the world.
Sepsis presents one of the greatest challenges to health systems worldwide, claiming approximately 11 million lives each year. That’s more than all cancers combined. In the United States, sepsis is the number one cause of death in hospitals, claiming the lives of approximately 270,000 Americans each year. Sepsis is the number one cost of US hospitalization, costing our healthcare system nearly $62 billion annually. Finally, sepsis is the number one cause of 30-day US hospital readmissions, requiring nearly 20% of sepsis survivors to be re-hospitalized within 30 days and approximately 40% to be re-hospitalized within 90 days.
The current standard of care for patients at risk of sepsis relies on broad empiric protocols to administer antimicrobial therapy, despite the fact that such protocols are only optimal in approximately one half of cases. This is of particular concern given the recent report issued by the Centers for Disease Control and Prevention, or CDC, showing an alarming increase in antimicrobial resistance in the United States as a result of the widespread use of antibiotics during the COVID-19 pandemic.
The current standard of care also continues to rely on a positive blood culture to identify the presence of a bloodstream infection, which can take anywhere from one to five days to turn positive, and is widely understood to have poor sensitivity. This presents a serious health challenge, as each hour of delayed targeted antimicrobial treatment can increase mortality risk by up to 8%, demonstrating that early detection of sepsis causing pathogens and antibiotic resistance genes is crucial for optimal treatment decisions and improving patient outcomes.
Our aim at T2 Biosystems is to advance patient care by enabling faster, more accurate detection of sepsis causing pathogens and antibiotic resistance genes. We’re commercializing the first and only FDA cleared products able to detect sepsis causing pathogens directly from whole blood within three to five hours, eliminating the need to wait days for a positive blood culture. Our products empower clinicians to deliver faster targeted antimicrobial therapy by rapidly identifying sepsis causing pathogens and antibiotic resistance genes.
During the second quarter, the T2 Biosystems team generated total revenue of $5.9 million, including product revenue of $2.6 million and R&D revenue of $3.4 million. We entered into contracts for 12 T2Dx instruments during the second quarter, including six in the United States and six internationally.
I’ll now turn to an update on our corporate priorities. Starting with our first priority, accelerating our sales. We continue to pursue a commercial strategy focused on two objectives. One, expanding our global T2Dx instrument installed base, and two, significantly increasing our sepsis test revenue by driving adoption and increasing utilization among new and existing customers.
During the second quarter, we expanded our installed base by adding 12 new instruments, which brings our total instrument installed base to 155, including 94 in the United States and 61 internationally. We continue to sell or place instruments across all types of hospitals, including large teaching hospitals, large hospital systems, as well as smaller community hospitals.
Importantly, and consistent with the previous two quarters, all of our instruments sales and placements during the second quarter were for sepsis testing. Our teams, including sales, medical affairs, service and support, are closely aligned to execute on our implementation strategy.
We generated sepsis test panel revenue of $1.2 million, consistent with the prior-year period. I’m pleased to announce that, in July, we received a $600,000 order, the largest sepsis order in company history, which included four T2Dx instruments that are expected to ship in the second half of 2022 and sepsis test panels.
From an instrument pull-through perspective, in the United States, we achieved annualized sepsis tests utilization of $106,000 for legacy instruments. We continue to believe that annualized US sepsis test utilization will reach $200,000 per instrument and we have a number of customers that have already surpassed that target. We believe there is a significant market opportunity for our products, and we’re excited to expand our presence in new and existing customers.
During the second quarter, two US hospital customers ordered their second T2Dx instruments to support their growing sepsis testing needs. These customers continue to increase their utilization of our sepsis test panels, and have expanded the use cases across their sepsis management protocols. We view this as an important validation of our technology.
The first hospital, a large academic center in the Midwest, has adopted both the T2Bacteria panel and the T2Candida panel. In this account, we’re closely engaged with a champion who continues to articulate the benefits of our products throughout the hospital.
The second hospital, part of a large health system in New Jersey, is a longtime user of the T2Candida panel and has implemented its routine use based on their experience with the test and determination of its clinical benefits. Both hospitals serve as reference accounts supporting our ongoing commercial efforts.
Early in 2022, we set expectations regarding a potential decline in sales of our COVID-19 molecular diagnostic test, the T2SARS-CoV-2 panel, which we experienced during the second quarter. We view this development as a positive because it allows us to convert COVID-driven instruments to sepsis testing. As a reminder, we sold 47 T2Dx instruments to hospital microbiology labs during 2020, initially for COVID-19 testing, with the expectation that approximately 80% would convert to our sepsis test panels over time.
Nearly one half of the COVID-driven instruments reside within two large hospital systems. So we have the potential to convert a sizable number of these instruments through a centralized decision-making process. And we are in active discussion regarding their conversion to our sepsis test panels.
Outside the United States, we continue to see a significant opportunity for our products, as hospitals around the world face similar challenges when caring for patients suspected of sepsis. Our international go-to-market strategy includes working with distributors to sell and support our products. Our team of international business managers is focused on supporting our existing distributors, as well as expanding our international distribution network into more countries. We were pleased with the initial groundwork in Norway, Finland and Turkey after expanding our distribution to these countries earlier this year. We maintain a strong pipeline of geographic expansion opportunities and expect further expansion throughout 2022.
Finally, I’d like to highlight a recent publication from the CDC on antimicrobial resistance and its global impact that reinforces the importance of our products. The publication demonstrates the need to invest in proven prevention focused health actions, such as accurate laboratory detection and rapid response and control in order to address current and future antimicrobial resistance threats.
Antimicrobial resistance is a leading cause of death globally. As the COVID-19 pandemic weighed on healthcare facilities, resistant hospital onset infections and deaths both increased by at least 15% during the first year of the pandemic. We’re proud to offer a solution that helps address antimicrobial resistance by enabling clinicians to make more informed and timely decisions.
Moving to our second priority, enhancing our operations. To build a solid foundation for sustainable growth, we continue to take actions to create a more efficient business model. We have a number of ongoing initiatives to increase efficiencies across the business and we’ve taken recent actions that we expect to favorably impact future financial results.
In May, we implemented an important cost of goods improvement initiative for T2Bacteria and T2Candida test panels, resulting in a reduction in the manufacturing costs of those two products in future quarters. This further expands test panel gross margins, helps us achieve a faster return on deployed instruments, and provides an overall benefit for our razor/razorblade business model.
In June, we made changes to improve our overall cost structure, including reducing our workforce and operating expenses by approximately 20%. We expect these changes to favorably impact our financials during the second half of 2022.
Finally, our operations team has worked diligently to ensure uninterrupted supply of products to our customers. While supply chain challenges exist across the industry, our team remains confident in our ability to continue supplying our customers without interruption during the second half of 2022.
Moving to our third priority, advancing our pipeline. We continue to make substantial progress with the programs under our milestone-based product development contract awarded by the US Biomedical Advanced Research Development Authority, or BARDA, which is valued at up to $69 million.
As a reminder, in the first quarter, BARDA chose to exercise Option 2B of the contract following our team’s successful completion of the milestones described under Option 2A. We’re nearing completion of the milestones required under Option 2B, which is valued at $4.4 million and we anticipate the award of Option 3 during the third quarter of 2022.
We’re very excited about the entire portfolio of products in our pipeline, as each one represents a future growth driver.
Under our agreement with BARDA, we’re developing for diagnostic products that we believe have the potential to meaningfully advance standards of care and protect our nation from biothreat attacks. One, the T2Resistance panel; two, the T2Biothreat panel; three, the comprehensive panel to detect bloodstream infections and antimicrobial resistance; and four, the next generation instrument.
The T2Resistance panel is a direct from blood test panel designed to run on the T2Dx instrument and simultaneously detects 13 antibiotic resistance genes known to cause antibiotic resistant infections in just three to five hours.
We’re selling the T2Resistance panel in Europe under CE Mark, and we’re on a pathway to apply for US 510(k) prior to US commercialization. We initiated a US clinical trial for the T2Resistance panel in December 2021 and we’re currently enrolling patients at five hospitals. We plan to increase patient enrollment by adding three additional hospitals during the third quarter, and we anticipate completion of the trial in 2022, which provides the potential to file with the FDA as early as this year.
As a reminder, the T2Resistance panel previously received breakthrough device designation from the FDA, which provides for a prioritized FDA review process.
The T2Biothreat panel is a direct from blood tests panel designed to run on the T2Dx instrument and simultaneously detects six biothreat pathogens identified as threats by the US government. Like our sepsis test panels, the T2Biothreat panel is designed to provide results in three to five hours without the need to wait days for a positive blood culture.
We initiated a clinical evaluation for the T2Biothreat panel in December 2021 to support submission to the FDA. We have completed the negative arm of the study, and we’re currently testing positive samples in a high containment BSL-3 laboratory. We remain on track to file an FDA submission in 2022.
The comprehensive panel to detect bloodstream infections and antimicrobial resistance is a direct from blood tests panel designed to run on our next generation instrument and detect greater than 95% of all bloodstream infections caused by bacterial and candida pathogens, as well as antibiotic resistance markers identified as threats by the CDC in a single test, with a time to result of approximately three hours.
Think of it as combining our existing T2Bacteri, T2Candida and T2Resistance panels into a single test, significantly expanding the pathogen detection capabilities and accelerating the time to result. We believe the comprehensive panel will establish a new standard of care for the detection of sepsis causing pathogens and antibiotic resistance genes.
The next generation instrument is being developed in parallel with our comprehensive panel. The instrument is designed to be fully automated on demand and random access, similar to our T2Dx instrument, but incorporates faster turnaround times, and the ability to detect an increased number of pathogens and resistance genes from a single whole blood sample.
We’ve built multiple development units and are now in the process of conducting qualification testing prior to merging the comprehensive test panel with the instrument to initiate full scale systemwide testing. We believe that our next generation instrument and comprehensive panel have the potential to replace many blood cultures for patients at risk of sepsis.
Let’s shift to Lyme disease. Lyme is a debilitating disease caused by the bacteria Borrelia burgdorferi, and it’s transmitted to humans through the bite of infected ticks. Typical symptoms include fever, headache, fatigue and skin rash. If left untreated, infection spreads to joints, the heart and the nervous system. According to the CDC, an estimated 476,000 people are treated for Lyme disease each year in the United States.
New York based FAIR Health recently published results using its database of over 36 billion privately built US healthcare plans to carry out an analysis of Lyme disease. The analysis found diagnosis of Lyme disease rose 357% in rural areas in the United States between 2007 and 2021, prompting FAIR to conclude that Lyme disease have become a “illness of increasing national concern.”
Currently, there are no FDA cleared diagnostic test for the sensitive detection of early Lyme disease. Laboratory diagnosis of Lyme disease has traditionally used a two tier process for detecting the presence of antibodies in a patient’s blood.
In the case of Lyme disease, antibodies can take several weeks to develop, but patients may test negative using current FDA cleared diagnostics if a patient has been recently infected. We have developed the T2Lyme panel, a molecular diagnostic test designed to run on our FDA cleared T2Dx instrument and simultaneously detect the bacteria that cause Lyme disease directly from whole blood. We expect it to be used aid in the diagnosis of early Lyme disease.
In June, the US Patent and Trademark Office issued a patent covering the future Lyme panel, “NMR Methods and Systems for the Rapid Detection of Tick Borne Pathogens.”
In July, the FDA granted breakthrough device designation for our T2Lyme panel, which is intended to expedite development, assessment and review of a potential submission for market clearance.
In August, we submitted for additional funding through the LymeX Initiative. And we’re also pursuing other sources of non-dilutive funding for the T2Lyme panel.
As we announced last week, we’re exploring the potential to develop a rapid molecular diagnostic test for the detection of the monkeypox virus, including technical and commercial feasibility.
Monkey pox is a rare disease caused by infection with the monkeypox virus that is part of the arthropods virus family of viruses, which also contains smallpox. The main symptoms of monkeypox is a rash, but individuals may also present with flu-like symptoms. A rapid and accurate diagnosis of monkeypox is essential to expedite treatment and to limit exposure and spread of the disease. We believe it is possible to develop a molecular diagnostic tests on our platform, and we also believe non-dilutive funding may be available to assist in such development efforts.
Finally, we formed a scientific advisory board during the second quarter of 2022, comprised of leading clinicians and researchers in the area of infectious disease, laboratory medicine and pharmacy.
The Scientific Advisory Board is chaired by Roger Smith, Senior Vice President of Science, Research and Development at T2 Biosystems, and will provide insights on clinical utilization, product pipeline, preclinical development, clinical research, clinical data generation, and strategic guidance to advance the company’s mission.
With that, I’ll now turn the call over to John Sprague to provide a detailed update of our second quarter 2022 financial results and our financial outlook for the remainder of the year.
John Sprague
Thank you, John. Total revenue for the second quarter of 2022 was $5.9 million, a decrease of 12% compared to the prior-year period, driven by decreased COVID-19 test panel sales, offset by increased T2Dx instrument sales and BARDA contract activities.
Product revenue was $2.6 million, a decrease of 30% compared to the prior-year period. Research contribution revenues were $3.4 million, an increase of 11% compared to the prior-year period.
Product costs for the second quarter of 2022 were $5.1 million, an increase of $300,000 compared to the prior-year period, driven by increased T2Dx instrument sales and offset by decreased COVID-19 test panel sales.
Research and development expenses were $8 million, an increase of $2.6 million driven by increased BARDA contract activities.
Selling, general, administrative expenses for $7.8 million, an increase of $600,000, driven by increased commercial headcount.
Net loss for the second quarter of 2022 was $18 million, $0.10 per share, compared to a net loss of $12.5 million, $0.08 per share for the prior year period.
Cash, cash equivalents and restricted cash were $14.3 million as of June 30, 2022. This includes net proceeds of $4.5 million from the sale of 21.6 billion shares through the ATM facility during the second quarter. As John mentioned earlier, we also raised $22.9 million through the ATM facility after the end of the second quarter. We remain in compliance with the CRG loan covenants.
Our guidance for the full year of 2022 remains unchanged. We expect total revenue of $28 million to $31 million, including product revenue of $16 million to $17 million, and research contribution revenues of $12 million to $14 million. We continue to expect to close 60 to 72 T2Dx instrument contracts in 2022 and COVID-19 revenues decrease from $9.5 million to $3.5 million.
Thank you. And back to John Sperzel for closing remarks.
John Sperzel
Thank you, John. I’d like to provide an update on the compliance status with NASDAQ listing requirements. During the quarter, we presented a plan to NASDAQ to regain compliance, which included operating plans to organically drive our share price to compliance, as well as plans to implement a reverse stock split as may be required.
In June, we announced that NASDAQ hearing panel granted our request for an extension until November 1, 2022 to regain compliance with NASDAQ’s minimum bid price requirement.
Today, we filed our preliminary proxy statement for our annual stockholder meeting. One of the items to be voted on at the annual stockholder meeting is a request for stockholder approval to authorize a reverse stock split in the event we need this by November 1, 2022 to achieve the minimum bid price required by NASDAQ.
We urge our stockholders to review the proxy statement and vote their shares of common stock for the reverse stock split proposal. We believe it is in the best interest of T2 Biosystems and our stockholders to maintain our NASDAQ listing.
There are three main reasons listing on NASDAQ is important. One, it provides share liquidity at an efficient market price. Two, it enables more flexibility to finance the business. And three, it is a valuable source for attracting and retaining the most skilled talent.
Thank you for your consideration and efforts ensuring T2 Biosystems maintains its NASDAQ listing.
In light of the importance of this proposal to our stockholders and the fact that our shares are largely held by retail holders that traditionally do not vote in large numbers, as well as by brokers that have eliminated discretionary voting, we’ve taken certain steps to improve the chances of having this proposal approved.
The steps include, one, amending our bylaws to reduce the quorum requirement for the number of shares that need to be present at a meeting for the transaction of business, and two, issuing shares of preferred stock with limited special voting rights. These preferred shares are only permitted to vote on the proposals related to the reverse stock split and cannot vote against the interests of the common stockholders.
The purpose of the preferred shares is to amplify the vote of the common holders by submitting votes in the same exact proportion as the votes submitted by the common stockholders in order to achieve the vote threshold required by Delaware law. The reverse split proposal will only be approved if more common stockholders approve the reverse split than don’t approve the split.
In summary, we’re pleased with the continued execution across our three corporate priorities, which we believe are key to advancing the standard of care for patients at risk of sepsis.
We’ve worked diligently to reduce expenses and enable a sustainable business model. Our commercial team continued to expand the installed base of T2Dx instruments globally, which is important to increase sepsis test sales. Our operations team implemented important changes to increase product gross margins. Our R&D team continues to meet key milestones to advance our new product pipeline under our BARDA contract.
Our accomplishments during the second quarter reinforce our excitement about the future for T2 Biosystems and commitment to our leadership position for the rapid detection of sepsis-causing pathogens and antibiotic resistance genes.
I’d like to turn the call back over to the operator to open the line for questions. Operator?
Question-and-Answer Session
Operator
[Operator Instructions]. Our first question comes from Stephen Brozak with WBB Securities.
Stephen Brozak
Right off the bat, on the financial side, obviously, you’ve been using the ATM to make sure that you’ve got enough cash. But can you tell us, are you still using it?
John Sperzel
We are not currently using the ATM facility.
Stephen Brozak
Away from the financial, can you tell us in as much detail as possible – one of the things, obviously, is we’re still in this pandemic. What is the linkage that you’ve seen between COVID and sepsis, and as much detail as you can give would be greatly appreciated? And I’ve got one follow up after that place.
John Sperzel
Well, early on in the pandemic, we saw data coming from China, which we subsequently saw in Europe and then in the United States, showing that about 30% of the critically ill hospitalized COVID patients were at risk and, in fact, developed a bloodstream infection and sepsis. And that’s been a consistent number. We’ve had key opinion leaders talk about one out of every three of their critically ill hospitalized COVID patients having sepsis. And we’ve seen that data throughout. So, there’s nothing that we’ve seen that has changed about a 30% link between critically ill hospitalized COVID patients in sepsis.
Stephen Brozak
Given your understanding of obviously these – in terms of on the virus side and how quickly we’re able to go out there and put into effect a rapid diagnostic for COVID, what are the technological areas that we should be looking at when given your skills with monkeypox and what detail can you give us on that and I’ll hop back in the queue?
John Sperzel
Well, last week – or earlier this week, we announced that we were exploring the potential to develop a molecular diagnostic test for the monkeypox virus. And if you go back to early 2020 when we were contemplating the development of a molecular diagnostic test for SARS-CoV-2, once we made the decision to do that, our scientific team developed that test within just 90 days. And we launched that test, in fact, on the 90th day, under the FDA Emergency Use Authorization criteria. So I would say that was a demonstration of the scientific expertise of our team, as well as the versatility of the platform. We’ve always said that the platform was agnostic to sample type. We certainly have the only FDA cleared product able to detect sepsis causing pathogens directly from whole blood and we demonstrated the ability to develop COVID-19 molecular diagnostic tests using upper respiratory swab.
Today, all of the monkeypox tests – in fact, the one licensed from CDC to many companies requires a swab of a lesion, which we understand is very painful. And the lesions often don’t show up for weeks at a time. And we think that there is the potential to develop a direct from blood test for monkeypox virus and that’s something that we’re exploring.
Operator
[Operator Instructions]. Ladies and gentlemen, this concludes our question-and-answer session. I would like to turn the conference back over to Mr. John Sperzel for any closing remarks.
John Sperzel
Thank you very much for joining our second quarter 2022 earnings call. We appreciate your support and look forward to updating you next quarter.
Operator
The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.
Be the first to comment